As companies experiment with potential treatments and vaccines for COVID-19, regulators across the globe are trying to ensure high-level focus to harness synergies.
In the EU, for example, the research community is being urged to pool resources into large multi-center, multi-arm clinical trials as this would most likely generate the conclusive evidence